Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Thrombotic complications are common in patients with severe COVID-19 pneumonia with important consequences on the diagnostic and therapeutic management. We report a consecutive series of five patients on long-term oral anticoagulation therapy who presented to our hospital for severe COVID-19 pneumonia associated with segmental acute pulmonary embolism despite adherence to therapy and with an adequate anticoagulant range at the time of the event. Four patients were receiving a direct oral anticoagulant (two with edoxaban, one with rivaroxaban and one with apixaban) and one patient a vitamin K antagonist. No significant thrombotic risk factors, active cancer, or detectable venous thromboembolism were present. In all cases, elevated d-dimer and fibrinogen levels with a parallel rise in markers of inflammation were documented. The combination of these findings seems to support the hypothesis that considers the local vascular damage determined by severe viral infection as the main trigger of thrombi detected in the lungs, rather than emboli from peripheral veins.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Journal of thrombosis and thrombolysis - 53(2022), 3 vom: 28. Apr., Seite 576-580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Tano, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9NDF7JZ4M3 |
|---|
| Anmerkungen: |
Date Completed 12.04.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11239-021-02589-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332466574 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332466574 | ||
| 003 | DE-627 | ||
| 005 | 20231225215631.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11239-021-02589-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332466574 | ||
| 035 | |a (NLM)34708314 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Tano, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Thrombotic complications are common in patients with severe COVID-19 pneumonia with important consequences on the diagnostic and therapeutic management. We report a consecutive series of five patients on long-term oral anticoagulation therapy who presented to our hospital for severe COVID-19 pneumonia associated with segmental acute pulmonary embolism despite adherence to therapy and with an adequate anticoagulant range at the time of the event. Four patients were receiving a direct oral anticoagulant (two with edoxaban, one with rivaroxaban and one with apixaban) and one patient a vitamin K antagonist. No significant thrombotic risk factors, active cancer, or detectable venous thromboembolism were present. In all cases, elevated d-dimer and fibrinogen levels with a parallel rise in markers of inflammation were documented. The combination of these findings seems to support the hypothesis that considers the local vascular damage determined by severe viral infection as the main trigger of thrombi detected in the lungs, rather than emboli from peripheral veins | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulant | |
| 650 | 4 | |a Infectious diseases | |
| 650 | 4 | |a Pulmonary embolism | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 700 | 1 | |a Dede, Meghi |e verfasserin |4 aut | |
| 700 | 1 | |a Pellicelli, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Moschini, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Calvaruso, Elva |e verfasserin |4 aut | |
| 700 | 1 | |a Danzi, Gian Battista |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thrombosis and thrombolysis |d 1994 |g 53(2022), 3 vom: 28. Apr., Seite 576-580 |w (DE-627)NLM094439990 |x 1573-742X |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:3 |g day:28 |g month:04 |g pages:576-580 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11239-021-02589-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 3 |b 28 |c 04 |h 576-580 | ||